End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Covance : Dow, S&P 500 close slightly lower; semis boost Nasdaq | RE |
2014 | Covance : LabCorp to pay $6.1 billion for drug trial company Covance | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Corporate Officer/Principal | - | 23-03-05 | |
Hong Gang Bi
PRN | Corporate Officer/Principal | - | 07-07-31 |
Corporate Officer/Principal | 63 | 12-06-17 | |
Thomas G. Turi
PRN | Corporate Officer/Principal | - | 08-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Eisenberg
BRD | Director/Board Member | 62 | 15-02-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 82,842,141 | 56,052,052 ( 67.66 %) | 25,882,990 ( 31.24 %) | 67.66 % |
Company contact information
Labcorp Drug Development, Inc.
206 Carnegie Center
08540-6233, Princeton
+336-584-5171
http://www.covance.comSector
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- Stock
- Company Covance Inc.